cap-1002

January 31, 2023

WATCH: Capricor Data Update From Ongoing HOPE-2 Open Label Extension Trial – Webinar Recording

WATCH: Capricor Data Update From Ongoing HOPE-2 Open Label Extension Trial Capricor Therapeutics recently joined PPMD for a community webinar on January 25, 2023 to present recent data findings from the ongoing HOPE-2 open label…

Learn More

Capricor Announces Positive One-Year Results from HOPE-2 Open Label Extension Study Evaluating CAP-1002

Dr. Linda Marbán, CEO of Capricor Therapeutics, presented a Late-Breaking News session at PPMD’s 2022 Annual Conference, announcing positive 1-year efficacy results from the ongoing HOPE-2 open label extension study of CAP-1002 in non-ambulant Duchenne…

Learn More

The Lancet Publishes Positive Results from Capricor’s Phase 2 Study of CAP-1002 in Late-Stage Duchenne

Capricor Therapeutics has announced that The Lancet has published positive results from the company’s HOPE-2 Phase 2 clinical trial evaluating CAP-1002 in advanced stages of Duchenne. Findings from the study demonstrated that young men in the advanced stages…

Learn More

January 25, 2022

Capricor & Nippon Shinyaku Enter Partnership for Commercialization and Distribution of CAP-1002 in the U.S.

Capricor Therapeutics and Nippon Shinyaku (US subsidiary: NS Pharma) have announced that they have entered into an agreement for the exclusive commercialization and distribution in the United States of CAP-1002, Capricor’s novel cell therapy candidate…

Learn More

November 8, 2021

Recap: Recent Research Updates

Welcome to FALL Time flies! Over the past few months, we have seen a number of announcements regarding drug development, changes to clinical trials, and new trials opening or on the horizon. For many, it…

Learn More

WATCH: Capricor’s HOPE-2 Final 12-Month Data – Webinar Recording

Capricor Therapeutics recently announced positive final 12-month results from the HOPE-2 Trial. HOPE-2 was a randomized, double-blind, placebo-controlled study focused on later-stage Duchenne patients. On June 3, 2020, Capricor joined PPMD for a webinar to…

Learn More

Capricor Announces Positive Top-Line Final Results from HOPE-2 Study

PPMD is excited to learn that Capricor Therapeutics has announced positive top-line 12-month results of the HOPE-2 clinical trial using CAP-1002 to treat non-ambulatory patients with Duchenne. Capricor has reported that the placebo patients in…

Learn More

October 9, 2019

2019 World Muscle Society Update – Day 4

This week, PPMD’s Abby Bronson, SVP of Research Strategy and Eric Camino, PhD, Director of Research and Clinical Innovation are attending the annual World Muscle Society (WMS) meeting, this year in Copenhagen, Denmark. Below, Abby…

Learn More

October 7, 2019

2019 World Muscle Society Update – Days 2 & 3

This week, PPMD’s Abby Bronson, SVP of Research Strategy and Eric Camino, PhD, Director of Research and Clinical Innovation are attending the annual World Muscle Society (WMS) meeting, this year in Copenhagen, Denmark. Below, Abby…

Learn More

WATCH: Capricor’s HOPE-2 Interim Analysis – Webinar Recording

On Wednesday, July 17, 2019, Capricor joined Parent Project Muscular Dystrophy for a webinar to update the community on Capricor’s HOPE-2 clinical program, following the company’s announcement of positive results from their interim analysis in…

Learn More